MedWatch

Amgen to acquire Nuevolution in million-dollar deal

US drug group Amgen has offered to acquire its Danish partner Nuevolution for USD 167 million - an increase by 169 percent relative to Nuevolution's closing price Tuesday this week. The board recommends that the shareholders accept the offer. 

Foto: Kevin Grønnemann

US drug group Amgen is about to acquire Danish biotech firm Nuevolution.

Wednesday this week, Amgen announced its offer to buy all shares in Nuevolution for SEK 32.5 per share. The total acquisition price amounts to SEK 1.61 billion (USD 167 million).

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier